Esophageal Diseases News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Endoscopic, histologic improvements in EoE sustained at 52 weeks with etrasimod

WASHINGTON — Once-daily etrasimod 1 mg and 2 mg was well-tolerated and sustained improvements in histological and endoscopic features of eosinophilic esophagitis, as well as patient symptoms, through 52 weeks of treatment, according to data. “Etrasimod is a an oral, once-daily selective sphingosine 1-phosphate receptor modulator for the treatment of moderately to severely active

United statesBykate burbaEvans dellonHeather bieleUniversity of north carolina school medicineEsophageal diseasesNorth carolina schoolDigestive diseaseDigestive disease weekEoe histology scoring systemEoe endoscopic reference scorePatient global impressionDysphagia symptom questionnaire

Eohilia Gets FDA Approval for Swallowing Disorder Eosinophilic Esophagitis

Eohilia is the first FDA-approved treatment specifically for eosinophilic esophagitis, a rare inflammatory disease of the esophagus.

United statesErin syversonEvan dellonUniversity of north carolinaDrug administrationBrandon monkBusiness unitEsophageal diseasesNorth carolinaEosinophilic gastrointestinal disease programBoston children

Dupilumab for EoE: How Is it Improving Treatment?

The drug was a boon for many patients, mainly those with moderate to severe disease, but cost and insurance approvals posed challenges.

University of north carolinaNorth carolinaUnited statesNew yorkRegeneron sanofiPhilip katzEvan dellonDrug administrationUniversity of north carolina at chapel hillMajor advanceWeill cornell medicineNew york cityMedscape medicalNew england journalEsophageal diseasesChapel hill

Q&A: Improved outcomes anticipated with dupilumab for children with EoE

Q&A: Improved outcomes anticipated with dupilumab for children with EoE
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Dupilumab dupixentEvans dellonSchool of medicineEsophageal diseases

Gastroenterology Month in Review: January 2024

Our January 2024 Month in Review spotlights the FDA approval of a new indication of dupilumab (Dupixent) for pediatric eosinophilic esophagitis, new clinical trial data, and research about the prevention and management of IBD.

Evan dellonDupilumab dupixentJulie khlevnerDrug administrationUniversity of north carolina chapel hillContemporary pediatricEsophageal diseasesNorth carolina chapel hillPediatric gastrointestinal motility centerColumbia university medical centerInflammatory bowel diseaseEosinophilic esophagitisUlcerative colitis